Moleculin Biotech Stock Bond Positions Weight
MBRX Stock | USD 1.67 0.14 7.73% |
Moleculin Biotech fundamentals help investors to digest information that contributes to Moleculin Biotech's financial success or failures. It also enables traders to predict the movement of Moleculin Stock. The fundamental analysis module provides a way to measure Moleculin Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Moleculin Biotech stock.
Moleculin | Bond Positions Weight |
Moleculin Biotech Company Bond Positions Weight Analysis
Moleculin Biotech's Percentage of fund asset invested in fixed income securities. About 30% of U.S. mutual funds invest in bonds.
Moleculin Bond Positions Weight Driver Correlations
Understanding the fundamental principles of building solid financial models for Moleculin Biotech is extremely important. It helps to project a fair market value of Moleculin Stock properly, considering its historical fundamentals such as Bond Positions Weight. Since Moleculin Biotech's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Moleculin Biotech's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Moleculin Biotech's interrelated accounts and indicators.
Click cells to compare fundamentals
Funds that have over 60% of asset value invested in bonds or or other fixed income securities would usually attract conservative investors.
Competition |
In accordance with the recently published financial statements, Moleculin Biotech has a Bond Positions Weight of 0.0%. This indicator is about the same for the Biotechnology average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
Moleculin Biotech Current Valuation Drivers
We derive many important indicators used in calculating different scores of Moleculin Biotech from analyzing Moleculin Biotech's financial statements. These drivers represent accounts that assess Moleculin Biotech's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Moleculin Biotech's important valuation drivers and their relationship over time.
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Market Cap | 37.3M | 47.1M | 50.0M | 30.3M | 25.4M | 27.4M | |
Enterprise Value | 26.9M | 32.2M | (20.8M) | (12.4M) | 2.5M | 2.3M |
Moleculin Fundamentals
Return On Equity | -1.41 | ||||
Return On Asset | -0.57 | ||||
Current Valuation | (3.65 M) | ||||
Shares Outstanding | 3.19 M | ||||
Shares Owned By Insiders | 3.30 % | ||||
Shares Owned By Institutions | 15.34 % | ||||
Number Of Shares Shorted | 20.66 K | ||||
Price To Earning | (3.81) X | ||||
Price To Book | 0.72 X | ||||
EBITDA | (29.5 M) | ||||
Net Income | (29.77 M) | ||||
Cash And Equivalents | 58 M | ||||
Cash Per Share | 2.03 X | ||||
Total Debt | 574 K | ||||
Debt To Equity | 0.01 % | ||||
Current Ratio | 10.47 X | ||||
Book Value Per Share | 3.36 X | ||||
Cash Flow From Operations | (24.1 M) | ||||
Short Ratio | 0.36 X | ||||
Earnings Per Share | (12.04) X | ||||
Target Price | 18.0 | ||||
Number Of Employees | 18 | ||||
Beta | 1.86 | ||||
Market Capitalization | 5.33 M | ||||
Total Asset | 38.22 M | ||||
Retained Earnings | (131.6 M) | ||||
Working Capital | 19.46 M | ||||
Current Asset | 28.09 K | ||||
Current Liabilities | 772.79 K | ||||
Net Asset | 38.22 M |
About Moleculin Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Moleculin Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Moleculin Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Moleculin Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Moleculin Stock Analysis
When running Moleculin Biotech's price analysis, check to measure Moleculin Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moleculin Biotech is operating at the current time. Most of Moleculin Biotech's value examination focuses on studying past and present price action to predict the probability of Moleculin Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Moleculin Biotech's price. Additionally, you may evaluate how the addition of Moleculin Biotech to your portfolios can decrease your overall portfolio volatility.